Bariatric Dose-ranging Study With Dexmedetomidine

Phase 4

Withdrawn

• Conditions: Abdominal Surgery Patients

• Registration Number: NCT00363935
• Lead Sponsor: University of Texas Southwestern Medical Center

Brief Summary

After obtaining informed consent,80 morbidly obese ASA II-III patients undergoing laparoscopic bariatric surgery procedures would be randomly assigned to one of four study groups at UTSWMC at Dallas.Hemodynamic paarameters, recovery times, postoperative pain scores, the need for rescue analgesics and side effects will be recorded.The purpose of this study is to determine the optimal linfusion rate of dexmedetomidine for maintaining cardiovscular stability during general anesthesia.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2006-08-10
• Study First Submitted QC: 2006-08-10
• Study First Posted: 2006-08-15
• Study Start: 2007-01-01
• Primary Completion: 2007-01-01
• Study Completion: 2007-01-01
• Status Verified: 2019-01
• Last Update Submitted: 2019-01-15
• Last Update Posted: 2019-01-16

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Subjects may be included in the study only if they meet all of the following criteria:

1. Age 18 to 70 years
2. Undergo laparoscopic bariatric surgery requiring general anesthesia
3. Be capable of giving informed consent
4. ASA physical status I-III ( Appendix 1)

Exclusion Criteria

1. Subjects will be excluded from the study for any of the following reasons:
2. With history of hypertension and allergy to dexmedetomidine
3. Patients who have greater than first degree heart block.
4. Performing major intracavitary surgery procedures
5. Patients who are pregnant or breast-feeding
6. History of alcohol or drug abuse

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (1)

The University of Texas Southwestern MedicalCenter at Dallas; 🇺🇸 Dallas, Texas, United States